Skip to content

PENG Block Plus Lateral Femoral Cutaneous Nerve Block for Posterolateral-approached Total Hip Arthroplasty

PENG Block Combined to Lateral Femoral Cutaneous Nerve Block vs. PENG Block Combined to Wound Infiltration for Postoperative Analgesia Following Posterolateral-approached Total Hip Arthroplasty

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05432011
Acronym
PENG-FLAT
Enrollment
50
Registered
2022-06-24
Start date
2022-07-01
Completion date
2023-05-25
Last updated
2023-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative Pain, Acute Pain, Analgesia, Hip Arthropathy, Postoperative Complications

Brief summary

This study aims to analyze the effect of Pericapsular Nerve Group (PENG) Block combined with lateral femoral cutaneous nerve block vs. PENG block combined with wound infiltration for analgesia after elective hip replacement performed with a posters-lateral approach. Half of participants will receive a PENG Block combined with femoral lateral cutaneous nerve block, while the other half will receive PENG Block combined with wound infiltration

Interventions

PROCEDUREPENG Block

At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.

At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.

PROCEDUREWound Infiltration

At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.

Sponsors

Campus Bio-Medico University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elective hip replacement surgery performed with a poster-lateral approach * ASA physical status score \< 4

Exclusion criteria

* Contraindications to regional anesthesia * ASA physical status score ≥ 4 * Patient's refusal or inability to sign the informed consent * Allergies to any drug provided by the study protocol

Design outcomes

Primary

MeasureTime frameDescription
Static Pain Score24 hoursA numerical rating scale (NRS) from 0 (no pain) to 10 (worst imaginable pain) will be used to evaluate pain at rest during 24 hours after surgery
Dynamic Pain Score24 hoursA numerical rating scale (NRS) from 0 (no pain) to 10 (worst imaginable pain) will be used to evaluate pain on movement during 24 hours after surgery

Secondary

MeasureTime frameDescription
Quadriceps Strength24 hoursAbility to flex the knee against gravity
Ability to start physiotherapy during the first postoperative day24 hoursYES: the patient was able to start physiotherapy NO: the patient was not able to start physiotherapy during the first postoperative day due to pain or motor block
Morphine consumption24 hoursTotal of intravenous morphine (expressed in milligrams) administered during the first 24 hours after surgery
Incidence of block complications24 hoursAny complications or side effects of the blocks, such as local infection, intravascular injection of local anesthetics and immediate systemic toxicity. Moreover, incidence of nausea, vomiting and postoperative respiratory depression will be recorded
Hospital Length of Stay6 daysTotal Hospital length of Stay (expressed in days)
Ability to ambulate with the help of a walker during the first postoperative day24 hoursYES: The patient was able to ambulate with the help of a walker NO: The patient was not able to ambulate with the help of a walker due to pain or motor block
Range of hip motion24 hoursDegrees of hip flexion

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026